India Pharmaceuticals and Healthcare Report Q3 2013

NEW YORK, July 23, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

India Pharmaceuticals and Healthcare Report Q3 2013
http://www.reportlinker.com/p0135180/India-Pharmaceuticals-and-Healthcare-Report-Q3-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Includes 3 FREE quarterly updates

BMI View:

Despite slowing growth in the Indian pharmaceutical market in the first four months of 2013, top domestic firms continued to see strong double-digit growth in the latest quarter, outperforming multinational pharmaceutical firms. We maintain that the Indian government's cost concerns will continue to hinder revenue growth for multinational pharmaceutical firms, benefiting the domestic industry. In foreign markets, Indian pharmaceutical firms will have to be more vigilant with manufacturing practices or risk suffering losses due to drug recalls.

Headline Expenditure Projections

Pharmaceuticals: INR840bn (US$15.7bn) in 2012 to INR926.1bn (US$17.0bn) in 2013; +10.3% in local currency terms and +8.3% in US dollar terms. Forecast slightly downgraded from Q213 due to slower growth in the first four months of 2013.

BMI Industry View 7
SWOT 9
Political 11
Economic 13
Business Environment 15
Industry Forecast 17
Overall Market Forecast 17
Table: Pharmaceutical Sales, 2009-2017 18
Healthcare 19
Table: Total Healthcare Expenditure, 2009-2017 20
Table: Governmental Healthcare Expenditure, 2009-2017 21
Table: Private Healthcare Expenditure, 2009-2017 21
Prescription Drug 22
Table: Prescription Drug Sales, 2009-2017 23
Patented Drug Market Forecast 24
Table: Patented Drug Sales, 2009-2017 25
Generics 26
Table: Generic Drug Sales, 2009-2017 27
OTC 28
Table: OTC Medicine Sales, 2009-2017 29
Export/Import 29
Table: Pharmaceutical Trade, 2009-2017 30
Other Healthcare 31
Macroeconomic Forecasts 33
Macroeconomic Forecast 33
Table: Economic Activity 39
Industry Risk Reward Ratings 40
Rewards 40
Risks 40
Market Overview 42
Industry Trends And Developments 44
Epidemiology 44
Healthcare Sector 46
Healthcare Sector Developments 48
Healthcare Insurance 51
Research & Development 52
Table: R&D Expenditure* In Top 20 Indian Pharmaceutical Firms (By Market Capitalisation) (US$mn) 54
Clinical Trials 55
Foreign Direct Investment (FDI) 56
Biosimilars 58
Table: List Of Selected Biosimilars Developed By Indian Pharmaceutical Firms 59
Traditional Medicines 61
Regulatory Development 62
Regulatory Developments 62
Table: Department Of Pharmaceuticals' Responsibilities 64
Pharmaceutical Advertising 66
Pharmacovigilance 66
Intellectual Property Regime 67
Table: History Of The Indian Patent System 67
Table: A Series Of Setbacks For Innovative Pharmaceutical Firms 69
Pricing Policy 71
Compulsory Licences 73
Competitive Landscape 75
Pharmaceutical Sector 75
Key Pharmaceuticals And Healthcare Industry Developments 77
Domestic Industry 78
Pharmaceutical Distribution 79
Pharmaceutical Retail Sector 80
Company Profile 82
Cipla 82
Ranbaxy 85
Dr Reddy 89
Aurobindo 92
Pfizer 95
GSK 98
Novartis 101
Sanofi 104
Merck & Co 107
Demographic Forecast 110
Table: India's Population By Age Group, 1990-2020 ('000) 111
Table: India's Population By Age Group, 1990-2020 (% of total) 112
Table: India's Key Population Ratios, 1990-2020 113
Table: India's Rural And Urban Population, 1990-2020 113
Glossary 114
Methodology 116
Pharmaceutical Expenditure Forecast Model 116
Healthcare Expenditure Forecast Model 116
Notes On Methodology 117

To order this report:
Drug_and_Medication Industry: India Pharmaceuticals and Healthcare Report Q3 2013

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker